What’s Going On With Take-Two Interactive Stock Friday?

Take-Two's announcement of Grand Theft Auto VI's fall 2025 release date led to a lowered bookings forecast for the current fiscal year, following a previous surge in share value and a downward revision in February due to a delayed title release.

Take-Two Interactive Software, Inc. (NASDAQ:TTWO) shares are trading lower premarket at last check Friday.

Yesterday, after the closing bell, the company released fourth-quarter financial results, where it gave an initial outlook for fiscal 2025, including net Bookings of $5.55 billion to $5.65 billion.

Check This Out: Take-Two Interactive Shares Fall After Q4 Results, FY 2025 Outlook

The company announced a release date of fall 2025 for the highly anticipated Grand Theft Auto VI video game, leading to a reduction in its bookings forecast for the current fiscal year, Bloomberg reported.

One year ago, Take-Two shares soared after the company forecasted bookings surpassing $8 billion for the year ahead. In February, the company revised its projection downward to “a little above $7 billion.”

The adjusted forecast stems from a delayed release of a title by Take-Two’s Rockstar Games division, initially slated for 2025, the report read. Grand Theft Auto VI, anticipated to be a top-grossing entertainment property, follows the record-breaking success of its predecessor, Grand Theft Auto V, which sold 200 million copies. Reports from late March suggested a delay in the release of Grand Theft Auto VI, Bloomberg added.

The company’s fourth-quarter bookings decreased by 3% to $1.35 billion, as compared to $1.39 billion during last year’s fiscal fourth quarter. Net Bookings from recurrent consumer spending decreased 2%, accounting for 79% of total Net Bookings.

Price Action: TTWO shares are trading lower by 2.45% to $142.50 premarket at last check Friday. 

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Image: victoria from Pixabay

Total
0
Shares
Related Posts
Read More

The Journal Of Clinical And Aesthetic Dermatology Published Arcutis Biotherapeutics’ Outcomes Of A Comprehensive Evaluation By An Expert Dermatologist Panel Assessing The Formulation Ingredients Of ZORYVE Topical Foam, 0.3%

Eight of nine experts expressed feeling "extremely confident" about prescribing ZORYVE foam to patients of diverse skin and hair types, including individuals with previous hair treatments, based on review of formulation

ARQT